LOGIN  |  REGISTER
Amneal Pharmaceuticals

Option Care Health to Participate in Upcoming Investor Conferences

November 03, 2025 | Last Trade: US$29.89 0.01 -0.03

BANNOCKBURN, Ill., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, will participate in the following upcoming investor conferences:

  • UBS Global Healthcare Conference, being held in Palm Beach, on Tuesday, November 11, 2025, at 3:30pm ET/2:30pm CT.
  • Jefferies London Healthcare Conference, being held in London, on Wednesday, November 19, 2025, at 3:30pm GMT/9:30am CT.
  • Bank of America Leveraged Finance Conference, being held in Boca Raton, on Tuesday, December 2, 2025, at 10:50am ET/9:50am CT.
  • Bank of America Home Care Conference, being held virtually, on Monday, December 8, 2025, at 10:50am ET/9:50am CT.

Webcast links and related presentation materials, if applicable, will be available online at https://investors.optioncarehealth.com.

About Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 8,000 team members including more than 5,000 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at optioncarehealth.com.

For Investor Inquiries:

Stephen Shulstein
Vice President, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Assertio

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page